HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

trabodenoson

Networked: 6 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Inorganic Chemicals: 9
- Electrolytes: 16106
  - Ions: 7857
    - Anions: 3501
      - Nitrates: 6625
        trabodenoson: 6
- Nitrogen Compounds: 67
  - Nitric Acid: 155
    - Nitrates: 6625
      - trabodenoson: 6
Organic Chemicals: 133
- Nitrates: 6625
  - trabodenoson: 6
Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - trabodenoson: 6

Experts

1.	Rich, Cadmus C: 4 articles (11/2019 - 10/2016)
2.	Baumgartner, Rudolf A: 3 articles (11/2019 - 10/2016)
3.	Albers, David S: 2 articles (11/2019 - 01/2018)
4.	McVicar, William: 2 articles (10/2016 - 10/2016)
5.	Qiu, Tina Guanting: 1 article (03/2021)
6.	Hijikata, Atsushi: 1 article (01/2020)
7.	Kanaya, Shigehiko: 1 article (01/2020)
8.	Nakae, Setsu: 1 article (01/2020)
9.	Ota, Motonori: 1 article (01/2020)
10.	Shionyu, Masafumi: 1 article (01/2020)

Related Diseases

1.	Ocular Hypertension (Glaucoma, Suspect) 10/01/2016 - "Twice-daily ocular doses of trabodenoson, from 50 to 500 mcg, were well tolerated and showed a dose-related decrease in IOP that was statistically significant and clinically relevant at 500 mcg in patients with ocular hypertension or POAG." 10/01/2016 - "A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabodenoson in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma." 10/01/2016 - "To evaluate the safety and ocular hypotensive efficacy of 4 trabodenoson doses administered twice daily over 14 or 28 days in subjects with ocular hypertension or primary open-angle glaucoma (POAG). "
2.	Open-Angle Glaucoma (Glaucoma, Open Angle) 10/01/2016 - "A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabodenoson in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma." 10/01/2016 - "To evaluate the safety and ocular hypotensive efficacy of 4 trabodenoson doses administered twice daily over 14 or 28 days in subjects with ocular hypertension or primary open-angle glaucoma (POAG). "
3.	Dry Eye Syndromes (Dry Eye Syndrome) 01/01/2018 - "Topical ocular delivery of trabodenoson significantly improves the clinical and histopathological signs associated with dry-eye disease in mice. " 01/01/2018 - "Efficacy of Trabodenoson in a Mouse Keratoconjunctivitis Sicca (KCS) Model for Dry-Eye Syndrome." 01/01/2018 - "Twice-daily topical (ocular) administration of trabodenoson increased tear levels and reduced corneal fluorescein staining (P < 0.05) as compared with vehicle-treated eyes in a mouse model of dry-eye disease. " 01/01/2018 - "To determine the efficacy of trabodenoson, an adenosine mimetic with highly selective adenosine A1 receptor binding properties, in a preclinical mouse model for dry-eye disease. "
4.	Keratoconjunctivitis Sicca 01/01/2018 - "Efficacy of Trabodenoson in a Mouse Keratoconjunctivitis Sicca (KCS) Model for Dry-Eye Syndrome."
5.	Eye Pain 10/01/2016 - "The most common ocular AE was eye pain (9.5% and 3.6%, respectively), with a single observation of ocular hyperemia (200 μg trabodenoson). " 10/01/2016 - "The most common adverse events (AEs) for trabodenoson and placebo were headache (25.0% vs. 33%, respectively) and eye pain (11.1% vs. 4.2%, respectively). "

Related Drugs and Biologics

1.	Adenosine (Adenocard)
2.	Adenosine A1 Receptor
3.	Matrix Metalloproteinases (MMPs)
4.	Fluorescein (Funduscein)
5.	Ophthalmic Solutions (Eye Drops)
6.	carfilzomib
7.	tecadenoson
8.	sinefungin

Related Therapies and Procedures

1.	Ophthalmic Administration